Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue        
Revenue
Other revenue 233 1,121
Total revenue 233 1,121
Operating expenses:        
Research and development, net of reimbursements 4,708 3,788 12,615 11,446
General and administrative 1,994 1,825 5,422 4,512
Total operating expenses 6,702 5,613 18,037 15,958
Loss from operations (6,469) (5,613) (16,916) (15,958)
Other income:        
Interest income - net 46 73 152 123
Total other income 46 73 152 123
Net loss (6,423) (5,540) (16,764) (15,835)
Deemed dividend for warrant down-round protection provision (1)
Net loss applicable to common stockholders $ (6,423) $ (5,540) $ (16,764) $ (15,836)
Net loss per share of common stock – basic and diluted (in Dollars per share) $ (0.3) $ (0.36) $ (0.84) $ (1.46)
Weighted average shares of common stock outstanding, including outstanding pre-funded warrants– basic and diluted (in Shares) 21,539,455 15,432,857 20,060,315 10,875,712